longboard pharmaceuticals is a team driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. longboard's proprietary pipeline includes multiple potentially first- or best-in-class programs with broad clinical utility. longboard is evaluating lp352, a next-generation 5-ht2c agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or dees. longboard is also evaluating lp143, a centrally acting, full agonist of the cannabinoid type 2 receptor (cb2), and lp659, a centrally acting, next-generation, highly selective s1p receptor modulator.
Company profile
Ticker
LBPH
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
LBPH stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
10 Jun 24
8-K
Material Modifications to Rights of Security Holders
24 May 24
10-Q
2024 Q1
Quarterly report
2 May 24
8-K
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
2 May 24
8-K
Regulation FD Disclosure
15 Apr 24
ARS
2023 FY
Annual report to shareholders
12 Apr 24
DEFA14A
Additional proxy soliciting materials
12 Apr 24
DEF 14A
Definitive proxy
12 Apr 24
PRE 14A
Preliminary proxy
28 Mar 24
8-K
Unregistered Sales of Equity Securities
26 Mar 24
Transcripts
Latest ownership filings
4
PAUL J SEKHRI
24 May 24
4
PHILLIP M SCHNEIDER
24 May 24
4
Casey Lynch
24 May 24
4
Goff Corinne Le
24 May 24
4
Vincent Aurentz
24 May 24
SC 13G/A
FMR LLC
11 Mar 24
SC 13G/A
Cormorant Asset Management, LP
14 Feb 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G/A
HBM Healthcare Investments (Cayman) Ltd.
13 Feb 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 54.64 mm | 54.64 mm | 54.64 mm | 54.64 mm | 54.64 mm | 54.64 mm |
Cash burn (monthly) | (no burn) | (no burn) | 6.04 mm | 5.24 mm | 5.06 mm | 4.41 mm |
Cash used (since last report) | n/a | n/a | 16.71 mm | 14.51 mm | 14.00 mm | 12.21 mm |
Cash remaining | n/a | n/a | 37.93 mm | 40.13 mm | 40.64 mm | 42.43 mm |
Runway (months of cash) | n/a | n/a | 6.3 | 7.7 | 8.0 | 9.6 |
Institutional ownership, Q4 2023
34.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 0 |
Closed positions | 51 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 38.75 mm |
Total shares | 11.46 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
PFE Pfizer | 3.98 mm | $19.34 mm |
ARNA Arena Pharmaceuticals | 3.98 mm | $19.42 mm |
HBM Healthcare Investments | 1.35 mm | $0.00 |
Farallon Capital Partners | 1.17 mm | $0.00 |
Integrated Core Strategies | 987.71 k | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 May 24 | Vincent Aurentz | Stock Option Voting common stock | Grant | Acquire A | No | No | 18.94 | 22,500 | 426.15 k | 22,500 |
23 May 24 | Goff Corinne Le | Stock Option Voting common stock | Grant | Acquire A | No | No | 18.94 | 22,500 | 426.15 k | 22,500 |
23 May 24 | Casey Lynch | Stock Option Voting common stock | Grant | Acquire A | No | No | 18.94 | 22,500 | 426.15 k | 22,500 |
23 May 24 | Schneider Phillip M | Stock Option Voting common stock | Grant | Acquire A | No | No | 18.94 | 22,500 | 426.15 k | 22,500 |
23 May 24 | Sekhri Paul J | Stock Option Voting common stock | Grant | Acquire A | No | No | 18.94 | 22,500 | 426.15 k | 22,500 |
News
Evercore ISI Group Maintains Outperform on Longboard Pharmaceuticals, Raises Price Target to $57
20 Jun 24
Cantor Fitzgerald Reiterates Overweight on Longboard Pharmaceuticals, Maintains $60 Price Target
20 Jun 24
B. Riley Securities Maintains Buy on Longboard Pharmaceuticals, Raises Price Target to $36
11 Jun 24
HC Wainwright & Co. Reiterates Buy on Longboard Pharmaceuticals, Maintains $60 Price Target
11 Jun 24
Longboard Pharmaceuticals Announces Interim Results From 52-Week Open-Label Extension Of PACIFIC Study Evaluating Bexicaserin (LP352) In Participants With Developmental And Epileptic Encephalopathies
10 Jun 24
Press releases
Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
10 Jun 24
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
3 Jun 24
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
6 May 24
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
2 May 24
Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15
3 Apr 24